Combinatorial remission maintenance immunotherapy with HDC and low-dose IL-2 was evaluated in a phase III trial of 320 adult AML patients in 11 countries (the 0201 trial).13 Enrolled patients (n = 320, 18–84 years, median 57 years) were in confirmed CR1 (n = 261) or any subsequent CR (CR > 1, n = 59) and not eligible for upfront allo-SCT. The gene discussed is IL2; the disease is acute myeloid leukemia.